1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-1-phenethyl-3-phenethylthiourea

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-1-phenethyl-3-phenethylthiourea
• 英文别名: 1-[3-(4-Hydroxy-3-methoxyphenyl)propyl]-1,3-bis(2-phenylethyl)thiourea
• 化学式: C₂₇H₃₂N₂O₂S
• 分子量: 448.629
• InChiKey: RGILFXFPQZTYDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  32
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  76.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(4-羟基-3-甲氧基-苯基)-丙醛 在 palladium on activated charcoal 氨 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 6.0h， 生成 1-(3-(4-hydroxy-3-methoxyphenyl)propyl)-1-phenethyl-3-phenethylthiourea
  参考文献：
  名称：

  Synthesis of N,N′,N″-trisubstituted thiourea derivatives and their antagonist effect on the vanilloid receptor

  摘要：

  Twenty-seven N,N',N"-trisubstituted thiourea derivatives were prepared. Among them, 1-[3-(4'-hydroxy-3'-methoxy- phenyl)-propyl]-1.3-diphenethyl-thiourea (81, IC50=0.32 muM), showed 2-fold higher antagonistic actively than that of capsazepine (3, IC50 = 0.65 muM) against the,anilloid receptor in a Ca-45(2+)-influx assay. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)01040-5

文献信息

• Novel thiourea derivatives and the pharmaceutical compositions containing the same
  申请人：——

  公开号：US20030153596A1

  公开（公告）日：2003-08-14

  The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新型硫脲衍生物，作为辣椒素受体（VR）的调节剂，以及含有该衍生物的药物组合物。作为与辣椒素受体活性相关的疾病，可以列举急性疼痛、慢性疼痛、神经痛、术后疼痛、偏头痛、关节痛、神经病变、神经损伤、糖尿病性神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合征、哮喘或慢性阻塞性肺病等呼吸道疾病、皮肤、眼睛或黏膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病。本发明提供了一种用于预防或治疗这些疾病的药物组合物。
• [EN] NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME<br/>[FR] NOUVEAUX DERIVES DE THIOUREA ET COMPOSITIONS PHARMACEUTIQUES RENFERMANT CEUX-CI
  申请人：PACIFIC CORP

  公开号：WO2002016318A1

  公开（公告）日：2002-02-28

  The present invention relates to novel thiourea derivatives as a modulator for vanilloid receptor (VR) and the pharmaceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

  本发明涉及一种新型硫脲衍生物，作为vanilloid受体（VR）的调节剂以及含有该化合物的制药组合物。作为与vanilloid受体活性相关的疾病，可以列举急性疼痛、慢性疼痛、神经病性疼痛、术后疼痛、偏头痛、关节痛、神经病变、神经损伤、糖尿病神经病变、神经退行性疾病、神经性皮肤疾病、中风、膀胱过敏、肠易激综合症、哮喘或慢性阻塞性肺疾病、皮肤、眼或粘膜刺激、发热、胃十二指肠溃疡、炎症性肠病和炎症性疾病等。本发明提供了用于预防或治疗这些疾病的制药组合物。
• EP1303483A4
  申请人：——

  公开号：EP1303483A4

  公开（公告）日：2004-11-03
• NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：PACIFIC CORPORATION

  公开号：EP1303483A1

  公开（公告）日：2003-04-23
• US8071650B2
  申请人：——

  公开号：US8071650B2

  公开（公告）日：2011-12-06